Form 4: Reprogrammed Interchange Sells Over 1.4M VOR Shares

Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc., sold over 1.4 million shares of common stock in early September 2025.

Summary

• Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc. (VOR), disposed of common stock over three consecutive days.
• On September 3, 2025, 554,612 shares were sold at a weighted average price of $1.9961 per share, with prices ranging from $1.99 to $2.01.
• On September 4, 2025, 453,016 shares were sold at a weighted average price of $1.9285 per share, with prices ranging from $1.91 to $2.005.
• On September 5, 2025, 400,000 shares were sold at a weighted average price of $1.9682 per share, with prices ranging from $1.935 to $1.995.
• Following these transactions, Reprogrammed Interchange LLC beneficially owns 35,476,939 shares of Vor Biopharma Inc. common stock.
• Reid Hoffman, also a director, is deemed a beneficial owner of securities held by Reprogrammed Interchange LLC due to shared control and indirect pecuniary interest, but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 3

Explanation: The filing indicates significant insider selling by a 10% owner and director, which is generally perceived as a negative signal by the market.

Negatives

• Reprogrammed Interchange LLC, a significant 10% owner and director, sold a substantial aggregate of 1,407,628 shares of Vor Biopharma Inc. common stock.
• The sales occurred over three days in early September 2025, potentially signaling a lack of confidence in the company's near-term prospects or valuation at the sale prices.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc., engaged in sales of common stock. Reid Hoffman, also a director and deemed beneficial owner through Reprogrammed Interchange LLC, is a related party to these transactions.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a lack of confidence in the company's future, potentially leading to downward pressure on the stock price.
• Management/Employees: Could face questions regarding the company's outlook if major shareholders are divesting.

Key Dates

Recommendation

The significant sale of over 1.4 million shares by a 10% owner and director, Reprogrammed Interchange LLC, suggests a potential lack of confidence in the company's near-term prospects or valuation at current price levels. Such insider selling often signals to the market that the stock may be overvalued or that negative developments are anticipated, warranting a 'sell' recommendation for investors.

Keywords

Vor Biopharma, VOR, Reprogrammed Interchange LLC, Reid Hoffman, Insider Selling, Form 4, Stock Sale, Beneficial Ownership